Novel MS solutions inspired by MIST.

Area of Science:

• Pharmacology and Toxicology
• Drug Development
• Analytical Chemistry

Background:

• Regulatory bodies (FDA, ICH) recommend early identification of drug metabolism differences between preclinical animal models and humans.
• Accurate metabolite quantification is vital for patient safety and avoiding late-stage drug development failures.
• Liquid Chromatography-Mass Spectrometry (LC-MS) is standard for metabolite detection but struggles with quantitative accuracy due to variable responses between parent drugs and metabolites.

Purpose of the Study:

• To address the limitations of LC-MS in quantifying drug metabolites in early drug development.
• To explore alternative analytical techniques for metabolite quantification in the absence of reference standards or radiolabeled compounds.

Main Methods:

• Evaluation of various detection techniques including UV, Corona Charged Aerosol Detection (CAD), radioactivity, Nuclear Magnetic Resonance (NMR), and low-flow nanospray LC-MS.
• Assessment of the precision of these methods for quantifying metabolites relative to a new chemical entity (NCE).

Main Results:

• Significant variations in LC-MS response between NCEs and their metabolites hinder direct quantitative analysis.
• Alternative methods (UV, CAD, radioactivity, NMR, nanospray) offer viable strategies for metabolite quantification.
• These methods provide sufficient precision for early clinical development needs, even without reference standards.

Conclusions:

• Early characterization of drug metabolism is essential for pharmaceutical development and patient safety.
• Alternative detection techniques can overcome LC-MS limitations for metabolite quantification.
• These approaches facilitate robust early-stage drug development by enabling precise metabolite measurement.